Share information
242.00 €
+0.46 %
22/05/2026 17:35
+0.46 %
Open
High
Low
Volume
242.40 €
242.90 €
240.40 €
184,447
Latest News
19-May-2026
BIMZELX[®](bimekizumab) demonstrates superior efficacy over SKYRIZI[®] (risankizumab) in psoriatic arthritis: BE BOLD Week 16 data
07-May-2026
UCB, Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies
03-May-2026
UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers
01-May-2026
UCB announces acquisition of IMIDomics’ Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs)